OQ
OQS.F Nanosonics Limited
- Market cap
- EUR 503M
- P/E
- 56.0x
- P/B
- 3.69x
- ROE
- 8.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is OQS.F undervalued?
Graham numberThe Graham number of Nanosonics Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanosonics Limited fundamental analysis
No fundamental analysis for Nanosonics Limited yet.
Nanosonics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanosonics Limited
Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infec…
Full company profileNanosonics Limited financial statements
Nanosonics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 67.5M | 60.6M | 84.6M | 101M | 102M | 120M | 168M | 172M | 199M | 204M |
| Gross Profit | 50.2M | 45.2M | 63.1M | 76.2M | 79.1M | 91.3M | 132M | 134M | 156M | 157M |
| Operating Income | 12.1M | 2.67M | 13.9M | 13.0M | 8.38M | -4.94M | 10.9M | 754K | 8.93M | 6.70M |
| EBITDA | 13.9M | 5.64M | 17.1M | 12.8M | 11.3M | 7.86M | 29.5M | 21.7M | 31.8M | 30.5M |
| Net Income | 26.2M | 5.75M | 13.6M | 10.1M | 8.58M | 3.74M | 19.9M | 13.0M | 20.7M | 17.8M |
| EPS | 0.09 | 0.02 | 0.05 | 0.03 | 0.03 | 0.01 | 0.07 | 0.04 | 0.07 | 0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 99.3M | 109M | 130M | 147M | 162M | 188M | 220M | 237M | 272M | 302M |
| Total Liabilities | 12.0M | 14.9M | 19.4M | 22.8M | 26.7M | 49.0M | 56.1M | 55.1M | 62.6M | 84.7M |
| Shareholders' Equity | 87.3M | 94.3M | 110M | 124M | 136M | 139M | 164M | 182M | 210M | 218M |
| Cash & Short-term Investments | 63.0M | 69.4M | 72.2M | 91.8M | 96.0M | 94.5M | 112M | 130M | 161M | 155M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 16.4M | 9.01M | 4.83M | 22.8M | 7.32M | 6.70M | - | - | - | - |
| Capital Expenditure | 1.07M | 2.31M | 1.68M | 1.88M | 1.23M | 6.79M | 3.57M | 2.52M | 8.72M | 5.14M |
| Free Cash Flow | 15.1M | 6.19M | 2.59M | 20.9M | 5.95M | -271K | 19.7M | 20.3M | 35.3M | 17.4M |
| Ratios | ||||||||||
| ROE | 30.0% | 6.1% | 12.4% | 8.2% | 6.3% | 2.7% | 12.1% | 7.1% | 9.8% | 8.2% |
| ROA | 26.4% | 5.3% | 10.5% | 6.9% | 5.3% | 2.0% | 9.0% | 5.5% | 7.6% | 5.9% |
| Net Profit Margin | 38.7% | 9.5% | 16.1% | 10.1% | 8.4% | 3.1% | 11.9% | 7.6% | 10.4% | 8.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nanosonics Limited dividends
Nanosonics Limited has not paid dividends in the last 10 fiscal years.
Who owns Nanosonics Limited
- Insiders 8.46%
- Institutions 60.76%
- Public & others 30.79%
- Shares outstanding 299M
- Free float 274M
Nanosonics Limited company profile
- Company name
- Nanosonics Limited
- Ticker
- OQS.F
- ISIN
- AU000000NAN9
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 508
- Fiscal year end
- June
- Address
- Building A, Macquarie Park, NSW, Australia, 2113
- Phone
- 61 2 8063 1600
- Website
- nanosonics.com.au
About Nanosonics Limited
Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infection control and decontamination products and related technologies. In addition, it is involved in the research, development, and commercialization of the CORIS system, an automated technology designed to transform flexible endoscope reprocessing. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
Nanosonics Limited management
10- Mr. Michael C. Kavanagh BSc, M.B.A.CEO, President, MD & Executive Director
- Mr. Jason Burriss B.Com., C.A.Chief Financial Officer
- Mr. Rod Lopez M.B.A.Chief Operating Officer
- Mr. Derek Minihane BSEE, J.D.Chief Technology Officer
- Mr. Sunny Pillai M.B.A.Chief Information Officer
- Mr. Jonathan Burdach Ph.D.Chief Medical Affairs & Scientific Officer
- Ms. Catherine StrongHead of Investor Relations & Corporate Communications
- Mr. Matthew Carbines B.Com., L.L.B.General Counsel & Company Secretary
- Ms. Kimberly Hill B.Sc.Chief Marketing Officer & Regional President of Asia Pacific
- Ms. Jodi Sampson M.A.I.C.D., M.B.A.Chief People & Culture Officer